Theriva Biologics
TOVX
48 hedge funds and large institutions have $15.7M invested in Theriva Biologics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
6% less funds holding
Funds holding: 51 → 48 (-3)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
44% less capital invested
Capital invested by funds: $27.9M → $15.7M (-$12.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$1.23M |
| 2 |
6CM
683 Capital Management
New York
|
+$1.07M |
| 3 |
VF
Virtu Financial
New York
|
+$150K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$131K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$81.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.26M |
| 2 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$345K |
| 3 |
Millennium Management
New York
|
-$200K |
| 4 |
ECM
Element Capital Management
New York
|
-$171K |
| 5 |
Squarepoint
New York
|
-$85K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $1K | – | – | – |
|
|
KF
52
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
54
BNP Paribas Financial Markets
Paris,
France
| $11 | – | – | – |
|
|
55
Alyeska Investment Group
Chicago,
Illinois
| – | -$1.26M | -201 | Closed |
|
|
EDRH
56
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$345K | -42 | Closed |
|
|
ECM
57
Element Capital Management
New York
| – | -$171K | -21 | Closed |
|
|
58
Squarepoint
New York
| – | -$85K | -10 | Closed |
|
|
PAG
59
Private Advisor Group
Morristown,
New Jersey
| – | -$14K | -2 | Closed |
|
|
PCM
60
Prelude Capital Management
New York
| – | -$11K | -1 | Closed |
|
|
AFNAS
61
American Financial Network Advisory Services
Calabasas,
California
| – | -$1K | – | – |
|
TOVX Hedge Fund Activity: Q4 2017 in Review
48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2017, worth a combined $15.7M — down 44% from $27.9M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TOVX and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 12 added.
The largest buyer was William Blair & Company, opening a new position worth an estimated $1.23M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.26M sold.
- 48 institutional investors held Theriva Biologics (TOVX) as of Q4 2017, down from 51 in Q3 2017.
- Funds reported $15.7M of Theriva Biologics stock for Q4 2017, down 44% quarter-over-quarter.
- 5 funds opened new Theriva Biologics positions in Q4 2017 and 6 closed out, a net change of -1 holder.
- The largest Theriva Biologics buyer in Q4 2017 was William Blair & Company, an estimated $1.23M added.
- The largest Theriva Biologics seller in Q4 2017 was Alyeska Investment Group, an estimated $1.26M sold.
Based on aggregated 13F filings for Q4 2017.